Securian Asset Management Inc. Lowers Stake in Gilead Sciences, Inc. $GILD

Securian Asset Management Inc. cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 65,007 shares of the biopharmaceutical company’s stock after selling 941 shares during the quarter. Securian Asset Management Inc.’s holdings in Gilead Sciences were worth $7,207,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Southland Equity Partners LLC boosted its position in shares of Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 92 shares during the last quarter. Twelve Points Wealth Management LLC boosted its position in shares of Gilead Sciences by 1.5% in the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after acquiring an additional 98 shares during the last quarter. Argentarii LLC boosted its position in shares of Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after acquiring an additional 99 shares during the last quarter. Lodestar Private Asset Management LLC boosted its position in shares of Gilead Sciences by 3.6% in the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 100 shares during the last quarter. Finally, RDA Financial Network boosted its position in shares of Gilead Sciences by 5.1% in the second quarter. RDA Financial Network now owns 2,129 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 103 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,500 shares of company stock valued at $8,281,540. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 0.2%

Shares of GILD stock opened at $123.11 on Tuesday. The stock has a market cap of $152.76 billion, a price-to-earnings ratio of 24.52, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a fifty-two week low of $85.60 and a fifty-two week high of $124.11. The firm’s 50 day moving average price is $115.27 and its two-hundred day moving average price is $110.62.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the previous year, the company posted $2.01 earnings per share. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on GILD shares. BMO Capital Markets raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. UBS Group raised their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $121.14.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.